Astec LifeSciences Limited
The Company is into manufacturing of agrochemical active ingredients (technical), bulk and formulations, intermediate products and it sells its products in India as well as exports them to approximately 24 countries.Astec also has undertaken a number of custom synthesis projects, for its clients in Europe, Japan and the US. It is present only in business to business sale (B2B).
What Astec files
- Others215
- Important54
- Updates30
- Board Meeting29
- Dividend/Bonus12
- QIP/Rights/Pref.8
Astec LifeSciences reported improved FY26 results: Total income reached ₹453.22 Cr, gross margin rose to 33.4%, and losses narrowed. Domestic sales surged 40.6%. A ₹249.35 Cr rights issue was completed. Focus continues on bolstering CDMO & R&D. A prior year regulatory penalty of ₹2.60 lakh each was paid to NSE/BSE.
Astec LifeSciences achieved strong FY26 revenue of ₹453.22 Cr, significantly cutting losses to ₹(80.88) Cr. A ₹249.35 Cr rights issue was completed, and credit ratings remained robust (ICRA AA- long-term, A1+ short-term). Strategic focus on CDMO and efficiency continues.
Astec LifeSciences achieved FY26 EBITDA break-even, with ₹453.22 Cr income and reduced losses to ₹(80.88) Cr. Gross margin improved to 33.4%. CDMO revenue was ₹235 Cr. A ₹249.35 Cr Rights Issue strengthened capital. Company invests in R&D; Labour Code changes impacted P&L.
Astec LifeSciences saw improved financial results. Total income rose to ₹453.22 Cr, achieving EBITDA break-even for the year from a prior loss. Net loss significantly reduced. Domestic sales jumped 40.6%, exports grew 6.7%. CDMO now drives 52% of sales. A Rights Issue successfully raised ₹249.35 Cr. New Chairperson and Executive...
Astec LifeSciences reports robust operational recovery in the recent fiscal year, achieving EBITDA break-even and narrowing loss to ₹80.88 Cr on ₹453.22 Cr revenue. Strategic CDMO business surged 2.5x in H2, supported by new facilities. A Rights Issue raised ₹249.35 Cr. New leadership includes a Chairperson and Executive Director. Labour...